Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interviews

Set Alert for Interviews

Finance Watch: Dementia Discovery Fund’s Behr Sees Early Investments Reviving Neuroscience Interest

Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each. 

Financing Innovation

The Biotech Rollercoaster Ride: From Lab To Buyout

After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.

Spain Financing

Cash Injection Puts Quell At Forefront Of Treg Therapy

The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.

Financing Liver & Hepatic

Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety

Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.

Emerging Company Profile Neurology

Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology

Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.

Cancer Launches

Plans For US Government To Negotiate Prices Not A Done Deal, Says AZ’s Dobber

While Democrat politicians - and most voters- want to see drug pricing negotiations introduced in the US for the first time, pharma leaders believe a deal on out of pocket costs will be agreed instead.

Commercial Companies

Earlier R&D Programs, Maturing Candidates Emerge From Bristol’s Pipeline

BMS is advancing a growing Phase I and II R&D pipeline, including a Factor XIa inhibitor with lower bleeding risk than current anticoagulants, as well as other internal and external research programs.

Strategy Cardiovascular

Lynk Pursues Own R&D Path But Partnerships Still Key

As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.

China Deals

Chinese Biotech Bets On Intravenous 3CL Antiviral Contender For COVID-19

While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.

China Coronavirus COVID-19

Institut Pasteur Korea CEO Talks COVID-19 Crisis, Drug And Vaccine Development

In this video fireside chat from the recent BIO-Europe Digital 2021 conference, the CEO of Institut Pasteur Korea outlines the research institute's role in managing the COVID-19 situation in the country, progress with the COVID-19 pipeline, issues related to the development of drugs and vaccines for the pandemic in South Korea, and her goals for the institute over the next few years.

South Korea Coronavirus COVID-19

Well-Funded Chinese Venture Races To Clinic Amid Reviving CNS Interest

SciNeuro’s latest in-licensing deals include three assets for major neurodegenerative diseases from Lilly and Mabylon, but the Chinese bioventure is looking beyond the shopping spree at what it sees as outstanding CNS needs.

China Deals

BIORCHESTRA On Overcoming Challenges For miRNA Therapeutics In Neurodegeneration

After being selected as an awardee of J&J’s Innovation QuickFire Challenge On Neuroscience in June, Korean bioventure BIORCHESTRA has been attracting attention from the global neuroscience community. CEO Branden Ryu talks to Scrip what makes its technology unique and how it aims to meet major unmet needs in RNA therapeutics and neurodegenerative disorders.

South Korea Neurology
See All
UsernamePublicRestriction

Register